시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 말초 T세포 림프종 시장 보고서(2025년)
Peripheral T-Cell Lymphoma Global Market Report 2025
상품코드 : 1720864
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

말초 T세포 림프종(PTCL) 시장 규모는 향후 몇 년 동안 큰 폭의 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 표적 치료의 발전, 개인 맞춤형 의약품의 채택 증가, 면역 치료 애플리케이션의 확대, 강력한 혁신 의약품 파이프라인, 신흥 시장에 대한 의료 투자 증가, 환자 접근 프로그램의 성장, 진단에 인공지능의 통합, 희귀 의약품에 대한 규제 인센티브, 병용 치료에 대한 관심 증가에 기인한 것으로 볼 수 있습니다. 이 기간 동안의 주요 트렌드로는 새로운 생물학적 제제의 개발, 유전자 편집 기술의 발전, 액체 생검 진단의 도입, AI 기반 치료 계획, CAR-T세포 치료의 혁신, 차세대 시퀀싱의 발전, 약물 전달을 위한 나노 기술의 사용, 개인 맞춤형 백신 개발, 이중 특이 항체의 출현, 임상시험 과정의 자동화가 있습니다.

림프종 발병률의 증가는 말초 T세포 림프종(PTCL) 시장의 성장을 견인할 것으로 예상됩니다. 림프종은 신체 면역 체계의 핵심 부분인 림프계에서 발생하는 암의 일종입니다. 림프종의 높은 발생률은 유전적 소인, 환경 노출, 엡스타인-바 바이러스와 같은 바이러스 감염, 면역 결핍 상태, 흡연 및 비만과 같은 생활 습관 요인과 관련이 있습니다. 말초 T세포 림프종은 성숙한 T세포에서 발생하여 다른 림프종 아형에 비해 공격적인 질병 행동, 면역 체계 기능 장애 및 낮은 치료 반응성을 유발함으로써 림프종 진행에 기여합니다. 예를 들어, 미국 암 협회의 통계에 따르면 2023년과 2024년 모두 비호지킨 림프종 신규 환자 수는 80,550명으로 추정됩니다. 결과적으로 높은 림프종 발병률은 PTCL 시장의 확장을 촉진하고 있습니다.

PTCL 시장을 선도하는 기업들은 치료 효과를 높이고 환자 예후를 개선하기 위해 디하이드로폴레이트 환원효소 억제제와 같은 혁신적인 치료법 개발에 우선순위를 두고 있습니다. 이러한 억제제는 DNA 합성과 세포 복제에 중요한 효소인 디하이드로폴레이트 환원효소의 활성을 차단하는 방식으로 작용합니다. 예를 들어, 2024년 12월 독일에 본사를 둔 제약 회사인 프레제니우스 카비(Fresenius Kabi AG)는 재발성 또는 불응성 PTCL 치료를 위해 폴로틴과 동등한 제네릭인 프랄라트렉세이트 주사제를 출시했습니다. 이번 출시로 회사의 종양학 포트폴리오가 확장되어 임상의와 환자에게 고품질의 비용 효율적인 치료 옵션을 제공할 수 있게 되었습니다. 이 주사는 20 mg/1mL 및 40 mg/2mL 단일 용량 바이알로 제공되며, 전체 반응률에 따라 신속 승인을 받았으며 확인 임상시험에 따라 계속 승인 여부가 결정됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas that develop from mature T-cells, a type of white blood cell crucial for immune function. PTCL can affect the lymph nodes, spleen, bone marrow, liver, and other organs, with symptoms including swollen lymph nodes, fever, night sweats, unexplained weight loss, skin rashes, and persistent fatigue.

The main types of PTCL include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma, and other subtypes. PTCL-NOS is a cancer originating from mature T-cells that do not fit into specific classifications. Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell therapy, and radiation therapy. The drugs used are classified into histone deacetylase (HDAC) inhibitors, monoclonal antibodies, alkylating agents, antimetabolites, and other categories. These medications are administered through oral and injectable routes and are utilized by various end users, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The peripheral T-cell lymphoma market research report is one of a series of new reports from The Business Research Company that provides peripheral T-cell lymphoma market statistics, including the peripheral T-cell lymphoma industry global market size, regional shares, competitors with the peripheral T-cell lymphoma market share, detailed peripheral T-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the peripheral T-cell lymphoma industry. This peripheral T-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral T-cell lymphoma market size has grown strongly in recent years. It will grow from 0.59 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increased awareness of rare lymphomas, the emergence of monoclonal antibodies, early orphan drug designations, advancements in hematologic cancer research, the growing adoption of stem cell transplants, improvements in diagnostic accuracy, the expansion of oncology healthcare infrastructure, and early innovations in immunotherapy.

The peripheral T-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in targeted therapies, the increasing adoption of personalized medicine, the expansion of immunotherapy applications, a robust pipeline of innovative drugs, rising healthcare investments in emerging markets, the growth of patient access programs, the integration of artificial intelligence in diagnostics, regulatory incentives for orphan drugs, and a growing focus on combination therapies. Key trends during this period include the development of novel biologics, advancements in gene editing technologies, the adoption of liquid biopsy diagnostics, AI-driven treatment planning, innovations in CAR-T cell therapy, progress in next-generation sequencing, the use of nanotechnology for drug delivery, personalized vaccine development, the emergence of bispecific antibodies, and automation in clinical trial processes.

The rising incidence of lymphoma is expected to drive the growth of the peripheral T-cell lymphoma (PTCL) market. Lymphoma is a type of cancer that originates in the lymphatic system, a key part of the body's immune system. The high occurrence of lymphoma is linked to genetic predisposition, environmental exposures, viral infections such as the Epstein-Barr virus, immunodeficiency conditions, and lifestyle factors such as smoking and obesity. Peripheral T-cell lymphoma contributes to lymphoma progression by arising from mature T-cells, leading to aggressive disease behavior, immune system dysfunction, and lower treatment responsiveness compared to other lymphoma subtypes. For example, according to the American Cancer Society's Facts and Figures, the estimated number of new non-Hodgkin lymphoma cases remained at 80,550 in both 2023 and 2024. As a result, the high incidence of lymphoma is fueling the expansion of the PTCL market.

Leading companies in the PTCL market are prioritizing the development of innovative treatments, such as dihydrofolate reductase inhibitors, to enhance treatment effectiveness and improve patient outcomes. These inhibitors work by blocking the activity of dihydrofolate reductase, an enzyme crucial for DNA synthesis and cell replication. For instance, in December 2024, Fresenius Kabi AG, a Germany-based pharmaceutical company, launched Pralatrexate Injection, a generic equivalent to Folotyn, for treating relapsed or refractory PTCL. This introduction expands the company's oncology portfolio, offering clinicians and patients a high-quality, cost-effective treatment option. The injection is available in 20 mg/1 mL and 40 mg/2 mL single-dose vials and received accelerated approval based on overall response rate, with continued approval dependent on confirmatory trials.

In August 2024, Citius Pharmaceuticals Inc., a US-based pharmaceutical company specializing in treatments for relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL), merged with TenX Keane Acquisition to establish Citius Oncology Inc. This merger aims to create a standalone oncology-focused company, advancing the commercialization of Lymphir and expanding its oncology pipeline. TenX Keane Acquisition Corp. is a US-based company focused on raising capital through an initial public offering (IPO) to acquire or merge with an existing business.

Major players in the peripheral T-cell lymphoma market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Company Limited, BeiGene Ltd., Daiichi Sankyo Company Limited, HUYA Bioscience International LLC, Zymeworks Inc., Genor Biopharma Co. Ltd., Kura Oncology Inc., Acrotech Biopharma LLC, Spectrum Pharmaceuticals Inc., Verastem Inc., Astellas Pharma Inc., Autolus Therapeutics plc.

North America was the largest region in the peripheral T-cell lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peripheral T-cell lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peripheral T-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral T-cell lymphoma market consists of revenues earned by entities by providing services such as diagnosis and screening services, treatment services, hospital and specialty care services, clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral T-cell lymphoma market also includes sales of corticosteroids, anthracyclines, vinca alkaloids, and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peripheral T-Cell Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peripheral t-cell lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for peripheral t-cell lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peripheral t-cell lymphoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Peripheral T-Cell Lymphoma Market Characteristics

3. Peripheral T-Cell Lymphoma Market Trends And Strategies

4. Peripheral T-Cell Lymphoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Peripheral T-Cell Lymphoma Growth Analysis And Strategic Analysis Framework

6. Peripheral T-Cell Lymphoma Market Segmentation

7. Peripheral T-Cell Lymphoma Market Regional And Country Analysis

8. Asia-Pacific Peripheral T-Cell Lymphoma Market

9. China Peripheral T-Cell Lymphoma Market

10. India Peripheral T-Cell Lymphoma Market

11. Japan Peripheral T-Cell Lymphoma Market

12. Australia Peripheral T-Cell Lymphoma Market

13. Indonesia Peripheral T-Cell Lymphoma Market

14. South Korea Peripheral T-Cell Lymphoma Market

15. Western Europe Peripheral T-Cell Lymphoma Market

16. UK Peripheral T-Cell Lymphoma Market

17. Germany Peripheral T-Cell Lymphoma Market

18. France Peripheral T-Cell Lymphoma Market

19. Italy Peripheral T-Cell Lymphoma Market

20. Spain Peripheral T-Cell Lymphoma Market

21. Eastern Europe Peripheral T-Cell Lymphoma Market

22. Russia Peripheral T-Cell Lymphoma Market

23. North America Peripheral T-Cell Lymphoma Market

24. USA Peripheral T-Cell Lymphoma Market

25. Canada Peripheral T-Cell Lymphoma Market

26. South America Peripheral T-Cell Lymphoma Market

27. Brazil Peripheral T-Cell Lymphoma Market

28. Middle East Peripheral T-Cell Lymphoma Market

29. Africa Peripheral T-Cell Lymphoma Market

30. Peripheral T-Cell Lymphoma Market Competitive Landscape And Company Profiles

31. Peripheral T-Cell Lymphoma Market Other Major And Innovative Companies

32. Global Peripheral T-Cell Lymphoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peripheral T-Cell Lymphoma Market

34. Recent Developments In The Peripheral T-Cell Lymphoma Market

35. Peripheral T-Cell Lymphoma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기